In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. In 2013, AbbVie (NYSE: ABBV) became a publicly ...

How Did AbbVie Fare In Q4? AbbVie’s revenue of $15.1 billion in Q4 reflected a 5.6% y-o-y growth. Looking at immunology, while Humira sales plunged 49% to $1.7 billion, Skyrizi sales surged 58% ...

AbbVie's Q3 earnings surpassed expectations with $3.00 EPS and $14.46 billion in revenue. Skyrizi and Rinvoq led growth; AbbVie also raised 2024 EPS guidance.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by investors including Pfizer Ventures, Novartis Venture Fund, Eli Lilly and ...